Amended Statement of Changes in Beneficial Ownership (4/a)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * van der Vaart Sandra D	2. Issuer Name and Ticker or Trading Symbol LABORATORY CORP OF AMERICA HOLDINGS [ LH ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) SVP, Global General Counsel
(Last)          (First)          (Middle) 531 SOUTH SPRING STREET	3. Date of Earliest Transaction (MM/DD/YYYY) 2/4/2020
(Street) BURLINGTON, NC 27215 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY) 2/6/2020	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	2/4/2020		A (2)		900		(3)	(3)	Common Stock	900	$0	2697 (4)	D
Non-qualified Stock Options (5)	$182.51	2/4/2020		A (2)		3900		2/4/2021 (6)	2/3/2030	Common Stock	3900	$0	3900	D

Explanation of Responses:
(1)	Each restricted stock unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock.
(2)	This amended form is filed to update the number of Employee Stock Options and Restricted Stock Units awarded and set for on Table II.
(3)	The Restricted Stock Units vest in three equal annual installments beginning on February 4, 2021.
(4)	This number reflects the aggregate number of Restricted Stock Units held by the reporting person.
(5)	Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan.
(6)	The option vests in three equal annual installments beginning on the date reflected in this column.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
van der Vaart Sandra D 531 SOUTH SPRING STREET BURLINGTON, NC 27215			SVP, Global General Counsel

Signatures
/s/ Sandra D. van der Vaart		2/7/2020
**Signature of Reporting Person		Date